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Background: Prostate cancer (PC) is the second most common cancer among men in the United States, and it
imposes a considerable threat to human health. A deep understanding of its underlying molecular mechanisms is
the premise for developing effective targeted therapies. Recently, deep transcriptional sequencing has been used as
an effective genomic assay to obtain insights into diseases and may be helpful in the study of PC.
Methods: In present study, ChIP-Seq data for PC and normal samples were compared, and differential peaks identified,
based upon fold changes (with P-values calculated with t-tests). Annotations of these peaks were performed.
Protein–protein interaction (PPI) network analysis was performed with BioGRID and constructed with Cytoscape,
following which the highly connected genes were screened.
Results: We obtained a total of 5,570 differential peaks, including 3,726 differentially enriched peaks in tumor samples
and 1,844 differentially enriched peaks in normal samples. There were eight significant regions of the peaks. The
intergenic region possessed the highest score (51%), followed by intronic (31%) and exonic (11%) regions. The
analysis revealed the top 35 highly connected genes, which comprised 33 differential genes (such as YWHAQ,
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein and θ polypeptide) from ChIP-Seq
data and 2 differential genes retrieved from the PPI network: UBA52 (ubiquitin A-52 residue ribosomal protein
fusion product 1) and SUMO2 (SMT3 suppressor of mif two 3 homolog 2) .
Conclusions: Our findings regarding potential PC-related genes increase the understanding of PC and provides
direction for future research.
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Prostate cancer (PC) is the second most common cancer
among men worldwide [1]. The most common symp-
toms are difficulty in urinating, erectile dysfunction and
problems during sexual intercourse [2,3]. Genetic back-
ground contributes to PC risk, as suggested by associa-
tions with race, family and specific gene variants [4,5].
Many genes have been found to be involved in PC. For
example, mutations in BRCA1 (breast cancer 1, early on-
set) and BRCA2 (breast cancer 2, early onset) are im-
portant risk factors for PC [6]. The authors of a previous
article reported that PTEN (phosphatase and tensin
homolog) deletions are related to tumor aggression in
PC [7].* Correspondence: yuzhangty5@hotmail.com; YuhaiZhangyu@163.com
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unless otherwise stated.Determining how proteins interact with DNA is im-
portant to fully view many biological processes and dis-
ease states. The information thus derived can lead to a
deeper understanding of tumor development. Chromatin
immunoprecipitation sequencing (ChIP-Seq) is used to
investigate interactions between chromatin-associated
protein and DNA [8]. It provides the ability to identify
the binding sites of any DNA-associated proteins [9].
CCCTC binding factor (CTCF) binds to three regularly
spaced repeats of the core sequence CCCTC, and it is
widely applied in ChIP-Seq [9,10].
ChIP-Seq analysis has recently been used to study PC.
The results of these studies provide some meaningful
ChIP-Seq data in comprehending the molecular mecha-
nisms of androgen receptors (AR) in PC cells, which
may be used to develop novel drugs [11,12]. Yu et al.
[13] systematically mapped the genomic landscape ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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PC cell lines and tissues. ChIP-Seq has also been used to
reveal direct binding of AR and ERG (v-ets avian
erythroblastosis virus E26 oncogene homolog) to the
promoter of glycine N-methyltransferase in VCaP (verte-
bral cancer of the prostate) cells [14]. There has been lit-
tle study of the identification of PC-related genes by
ChIP-Seq analysis.
Protein–protein interaction (PPI) networks provide
valuable information in the understanding of cellular
function and biological processes. With the tremendous
increase in human protein interaction data, the PPI net-
work approach is used to understand molecular mecha-
nisms of disease, particularly to analyze cancer-related
phenomena [15]. PPI networks also provide insights into
distinct topological features of cancer genes [16]. There-
fore, in the present study, we analyzed ChIP-Seq data
derived from PC samples and normal controls, and dif-
ferential peaks were screened out. Annotations were
given for those peaks, and PPI network analysis was per-
formed to identify critical genes related to PC.Methods
Data source
Two Sequence Read Archive files, SRR513122 for nor-
mal and SRR513123 for tumor, were downloaded from
National Center for Biotechnology Information Gene
Expression Omnibus database with accession number
[GEO:GSE38684] [17]. The original ChIP-Seq data were
acquired from two normal primary prostate epithelialFigure 1 Differential CCCTC binding factor binding peaks between the
location is shown in the upper panel. Blue peaks represent CCCTC bindingcells (PrEC cell lines) and three PC cell lines (LNCaP
cell lines) by Bert et al. [17].
Processing and alignment
Reads with low quality were first discarded. To prevent
high-quality reads from being rejected during quality-
filtering or assembly processes, we trimmed bases from
poor-quality ends of reads [18]. ChIP-Seq reads were
aligned to the human genome (hg19) using the Bowtie
tool [19], which allows up to two mismatches in the
alignment. Locations with one or more exact matches
were kept for further analysis.
Screening and annotation of differential peaks
Model-based analysis of ChIP-Seq (MACS) [20] was ap-
plied to identify peaks (read-enriched regions) from Se-
quence Alignment/Map (SAM) format files as well as
differential peaks between cancer and normal samples.
MACS is a command line tool designed to analyze ChIP-
Seq data in eukaryotes, especially in mammals [21]. The pa-
rameters for calling peaks are as follows: (1) effective gen-
ome size = 2.70e + 09, (2) bandwidth = 300 bp and (3) P-
value cutoff = 1.00e-10. To provide further functional con-
text for the biological interpretation, peaks with fold enrich-
ment scores above 2.95 were picked out and annotated
with respect to known genomic sequence features (such as
genes and transcripts) according to the hg19 refGenes data.
Some peaks of various widths were assigned to a gene
based on the closest transcription start sites (TSSs), then
the locations of those peaks were extracted by MACS.
DNA motifs were identified using MDSeqPos (P < 0.0001).prostate cancer sample and the normal sample. The chromosomal
factor binding peaks in these regions.
Figure 2 The distribution regions and motifs with annotation of differential peaks. (A) A pie chart of the peaks mapping to the splicing, upstream,
exonic, downstream, 5′ untranslated region (UTR5), UTR3, intronic and intergenic genomic regions. (B) One of the top enriched DNA binding motifs.
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Proteins (genes) work together to exert certain biological
functions, with the proteins exhibiting more interactions
with others likely to play more important roles in the
whole process. Therefore, PPI network analysis of the
genes obtained above was performed with BioGRID (Bio-
logical General Repository for Interaction Datasets) [22],
which is a public database of physical and genetic interac-
tions for all major model organism species (combined
score above 0.4). This network was then constructed using
Cytoscape [23], which is a software package available on
the internet for biological network visualization, data inte-
gration and interaction network generation.Results
Differential peaks between prostate cancer tissue samples
and normal samples
A total of 5,570 differential peaks were found between the
PC sample and normal sample (Additional file 1: Table S1
and Additional file 2: Table S2). Among these peaks, 3,726
peaks were differentially enriched in the PC sample and
1,844 peaks were differentially enriched in the normal
sample. Two typical differential binding regions which
were in the vicinity of POTEH (POTE ankyrin domain
family, member H) are shown in Figure 1. We found that,
in the tumor sample, both of these two peaks were signifi-
cantly higher than those in the same positions of the
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binding site in tumors. The widths of the two peaks in the
tumor sample were approximately 200 to 300 bp.
Annotation of differential peaks
Differential peak regions were annotated and their
functional consequence on genes were examined
(Additional file 3: Table S3). The most significantlyFigure 3 The protein–protein interaction network of differential peak
indicate that some interaction exists in two nodes, such as the same pathw
network was visualized with Cytoscape.regions of the peaks were shown in Figure 2A. The inter-
genic region was the highest with a score of 51%, followed
by the intronic region (31%) and the exonic region (11%).
Other regions of the peaks were upstream (2%), splicing
(1%), the 5′ untranslated region (5′ UTR) (1%), 3′ UTR
(1%) and downstream (1%). One of the top enriched DNA
binding motifs is shown in Figure 2B. The − log10 (motif
enrichment P-value) was 69.078.–related genes. Nodes stand for genes or interacting genes. Edges
ays, biological processes or molecular functions. The interaction
Zhang et al. European Journal of Medical Research 2014, 19:47 Page 5 of 7
http://www.eurjmedres.com/content/19/1/47Protein–protein interaction network of peak-associated
genes
The PPI network of peak-associated genes and some
other interactional genes is shown in Figure 3 (P < 0.05).
The network contains 4,920 protein nodes and 7,018
interaction edges. Genes closely related to others might
have important roles in biological processes. Therefore,
interactions between genes were calculated for each
gene, and the top 35 genes were obtained (Figure 4).
Among them, 33 differential genes were identified from
the ChIP-Seq data, and 2 others were derived from the
PPI network. Each of them had a neighbor number near
or above 100. UBA52 (ubiquitin A-52 residue ribosomal
protein fusion product 1), with the highest weight (above
500), was a PPI network–associated gene. Next, the sub-
sequent genes were identified from ChIP-Seq data, such
as YWHAQ (tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, θ polypeptide),
NEDD4 (neural precursor cell expressed, developmen-
tally downregulated 4, E3 ubiquitin protein ligase) and
EGFR (epidermal growth factor receptor). Some other
genes, including AR (androgen receptor), HAPA4
(heat shock 70 kDa protein 4), CDK9 (cyclin-dependent
kinase 9) and SUMO2 (SMT3 suppressor of mif two 3
homolog 2), may be PC-related.
Discussion
Unlike sequence-specific transcription activators such as
ER and p53, CTCF binding sites are ubiquitously and
universally present throughout the genome, and their
chromosomal distribution is strongly correlated with genes
[24]. Bert et al. used these data to identify the relationship
between long-range epigenetic activation and domain gene
deregulation, which is quite different from our results [17].
We used MACS was in the present study and found 5,570Figure 4 Top 35 highly connected genes in the network of differentia
Genes marked with asterisks are differential peak–related genes that were idifferential peaks comprising 3,726 differentially enriched
peaks in the PC sample and 1,844 differentially enriched
peaks in the normal sample. According to the annotation
results (Figure 2), CTCF binding sites were scattered in
chromosomes. About one-half of the CTCF binding sites
flanked genes. In addition, some differentially expression
genes were obtained with the PPI network analysis.
Figure 4 shows the top 35 highly connected genes in a
network of differential genes. Some of them are biomarkers
of PC. AR had the sixth most interactors in the network,
and the peak of it was enriched in the intergenic region of
chromosome X, which is in accordance with the results re-
ported by Taslim et al. [25]. The AR signaling axis plays a
critical role in PC development and progression [26]. In a
previous study, researchers discovered that AR is highly
expressed in PC and that it may inhibit PC progression by
suppressing AR expression and activity [27]. An inter-
national patent has been filed for the use of AR variants as
biomarkers and therapeutic targets in advanced PC [28].
CDK9 is a regulator of cell cycles. The peaks of CDK9
were aligned upstream of chromosome 9. Shore et al.
showed that one isoform of CDK9 was transcribed from
an alternative upstream promoter [29]. Gordon et al.
found that CDK9 regulated AR promoter selectivity and
cell growth through serine 81 phosphorylation [30]. The
combined inhibition of Cdk9 and Akt can be utilized to
induce apoptosis of metastatic PC cells [31].
EGFR is also an important player in the PPI network.
The position of differential peaks annotation was exonic
at chromosome 7. EGFR is the cell-surface receptor for
members of the epidermal growth factor family of extra-
cellular protein ligands [32]. EGFR overexpression may
serve as a reasonable target for therapeutic intervention
in this otherwise difficult-to-treat subset of PC patients
[33]. The progression of PC is accompanied by thel peak–related genes. The ordinate represents the degree of protein.
dentified from ChIP-Seq data.
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suggesting that it may play a crucial role in PC [34].
NEDD4, whose peak annotation was located in the
intergenic region of chromosome 15, was in the center
of the PPI network. It is a proto-oncogenic ubiquitin lig-
ase for PTEN, and its upregulation is found in many hu-
man cancers [35]. Farooqi et al. reported that SMURF
and NEDD4 interference offers therapeutic potential in
chaperoning genome integrity [36].
The peak of HSPA4 (heat shock protein 70 (HSP70))
was located in the intergenic region of chromosome 5.
HSPA4 has been implicated in PC [37,38], and it may
also be differentially regulated according to our analysis.
Kottke et al. found that induction of hsp70-mediated
Th17 autoimmunity can be exploited in immunotherapy
for metastatic PC [39].
SUMO2 was also included in the list. In previous stud-
ies, investigators have discovered the role of desumoyla-
tion in the development of PC [40–42]. Yang et al.
reported that small ubiquitin-like modifier isoforms 1, 2
and 3 are activated in human astrocytic brain tumors and
are required for glioblastoma cell survival. Therefore, we
speculated that SUMO2 might play a similar role in PC.
POTEH, located on chromosomes 21, may also be a
candidate for the immunotherapy of PC [43], which is
recorded in GeneCards as a PC-related gene. A previous
study showed that POTEH is expressed highly in PC, but
is limited in benign tissues [44].
Conclusions
Overall, we identified a number of key genes related to
PC by analyzing ChIP-Seq data in the present study.
These genes include AR, CDK9, EGFR, NEDD4, HSPA4
and SUMO4, and about one-half of them were located
in the intergenic regions of chromosomes with differen-
tial peak annotations. These genes may help enhance the
understanding of PC and also provides direction for fu-
ture research. Future research is needed to define their
roles in detail and subsequently develop effective molecu-
lar target therapies for PC.
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